Literature DB >> 10580194

Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence.

R Weiss1, J Dürnberger, S Mostböck, S Scheiblhofer, A Hartl, M Breitenbach, P Strasser, F Dorner, I Livey, B Crowe, J Thalhamer.   

Abstract

The present study outlines the characterization of a DNA-based immune response against the OspC antigen, one of the most promising candidates for a Borrelia vaccine. Balb/c mice were injected intradermally with plasmid DNA encoding the OspC gene (lacking the natural leader sequence) under transcriptional control of the cytomegalovirus (CMV) promotor. Immunization with this construct elicited only a marginal response, which was drastically improved by a fusion construct containing the human tissue plasminogen activator (hTPA) signal sequence. The results indicate that for DNA-based immunization against OspC an ER-targeting signal may be necessary for both antibody production as well as cellular immune responses.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10580194     DOI： 10.1016/s0264-410x(99)00338-2

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.

Authors:  R Wallich; A Siebers; O Jahraus; C Brenner; T Stehle; M M Simon
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine.

Authors:  Yuh-Pyng Sher; Su-I Lin; Kit Man Chai; I-Hua Chen; Shih-Jen Liu
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

3.  Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Authors:  Zhiwei Chen; Linqi Zhang; Chuan Qin; Lei Ba; Christopher E Yi; Fengwen Zhang; Qiang Wei; Tian He; Wenjie Yu; Jian Yu; Hong Gao; Xinming Tu; Agegnehu Gettie; Michael Farzan; Kwok-Yung Yuen; David D Ho
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 4.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

5.  Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.

Authors:  Haim Grosfeld; Sara Cohen; Tamar Bino; Yehuda Flashner; Raphael Ber; Emanuelle Mamroud; Chanoch Kronman; Avigdor Shafferman; Baruch Velan
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

Authors:  Wolfgang W Leitner; Matthew C Baker; Thomas L Berenberg; Michael C Lu; P Josef Yannie; Mark C Udey
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

7.  From sequence to antibody: genetic immunisation is suitable to generate antibodies against a rare plant membrane protein, the KAT 1 channel.

Authors:  Renate Gehwolf; Richard Weiss; Maximilian Gabler; Annette C Hurst; Adam Bertl; Josef Thalhamer; Gerhard Obermeyer
Journal:  FEBS Lett       Date:  2007-01-16       Impact factor: 4.124

8.  Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge.

Authors:  Gang Wang; Li Pan; Yongguang Zhang; Yonglu Wang; Zhongwang Zhang; Jianliang Lü; Peng Zhou; Yuzhen Fang; Shoutian Jiang
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

9.  The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine.

Authors:  Esther E Weinberger; Almedina Isakovic; Sandra Scheiblhofer; Christina Ramsauer; Katrin Reiter; Cornelia Hauser-Kronberger; Josef Thalhamer; Richard Weiss
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.